Gastrooesophageal cancer

10 trials 3 recruiting MedDRA PT
10 Registered trials
3 Recruiting
7 Unique sponsors
16 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 9
V Various (ATC V) 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Checkpoint inhibitor (PD-1) 2 substances
Antibody-drug conjugate (ADC) 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Checkpoint inhibitor (PD-L1) 2 substances
Monoclonal antibody (immune, humanized) 1 substance
Taxane 1 substance
Antimetabolite 1 substance
Platinum compound 1 substance
RAF/BRAF inhibitor 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 3 Phase I/II: 2 Phase I: 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

3 trials
  • BeOne Medicines AG Commercial
    TISLELIZUMAB
    2025-522862-58-00 6 countries 2026 n=63
    Recruiting
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB
    2023-509360-24-00 10 countries 2016 n=275
    Ended
  • Institut fuer Klinische Krebsforschung IKF GmbH Academic
    NIVOLUMAB; REGORAFENIB
    2023-505441-69-00 4 countries 2022 n=125
    Ended

Phase II/III

1 trial
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    ATEZOLIZUMAB; CALCIUM FOLINATE PENTAHYDRATE; DOCETAXEL; FLUOROURACIL; OXALIPLATIN
    2024-514945-12-00 1 country 2018 n=624
    Ended

Phase II

3 trials
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    CALCIUM FOLINATE PENTAHYDRATE; DOCETAXEL; DURVALUMAB; FLUOROURACIL; OXALIPLATIN
    2024-512980-29-00 1 country 2023 n=32
    Ended
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    DISODIUM FOLINATE; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZUMAB
    2024-513610-34-00 1 country 2023 n=30
    Ended
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    CALCIUM LEVOFOLINATE PENTAHYDRATE; NIVOLUMAB; OXALIPLATIN
    2024-519591-39-00 1 country 2025 n=84
    Recruiting

Phase I/II

2 trials
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN; PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-509307-33-00 4 countries 2024 n=26
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    CALCIUM FOLINATE PENTAHYDRATE; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB DERUXTECAN
    2024-518841-12-00 2 countries 2025 n=39
    Halted

Phase I

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 4 Phase II/III, Phase II, Phase I/II 0
Novartis Pharma AG Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase III 1
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase I/II 1
IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic 1 Phase II 1
Institut fuer Klinische Krebsforschung IKF GmbH Academic 1 Phase III 0
New trials by year
2022
1
2023
2
2024
2
2025
2
2026
1
← All indication landscapes